EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-21
DOI
10.1186/s13045-019-0814-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide
- (2019) Sebastian Burgos et al. MEDICINE
- Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
- (2019) Daisuke Ennishi et al. Cancer Discovery
- FoxP3 and Ezh2 regulate Tfr cell suppressive function and transcriptional program
- (2019) Shenda Hou et al. JOURNAL OF EXPERIMENTAL MEDICINE
- ANRIL and ANRASSF1 long noncoding RNAs are upregulated in gastric cancer
- (2019) Roghayeh Kangarlouei et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- EZH2 inhibitor GSK126 suppresses anti-tumor immunity by driving production of myeloid-derived suppressor cells
- (2019) Shuo Huang et al. CANCER RESEARCH
- Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas
- (2019) Jennifer K Lue et al. CLINICAL CANCER RESEARCH
- Propofol suppresses proliferation and migration of papillary thyroid cancer cells by down-regulation of lncRNA ANRIL
- (2019) Fumei Chen et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma
- (2019) Boheng Li et al. BLOOD
- Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas
- (2018) Malik Bisserier et al. BLOOD
- STAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner
- (2018) Shanshan Sun et al. CLINICAL CANCER RESEARCH
- Dual Role of EZH2 in Cutaneous Anaplastic Large Cell Lymphoma: Promoting Tumor Cell Survival and Regulating Tumor Microenvironment
- (2018) Shengguo Yi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
- (2018) Antoine Italiano et al. LANCET ONCOLOGY
- Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS
- (2018) Nasrin Rastgoo et al. LEUKEMIA
- Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
- (2018) Roland Schmitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estrogen receptor β promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network
- (2018) Jie Ding et al. ONCOGENE
- Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin’s Lymphoma
- (2018) Biao Lu et al. ACS Medicinal Chemistry Letters
- EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes
- (2018) Taylor Harding et al. Oncotarget
- Ezh2 Regulates Activation-Induced CD8+ T Cell Cycle Progression via Repressing Cdkn2a and Cdkn1c Expression
- (2018) Guobing Chen et al. Frontiers in Immunology
- Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors
- (2018) Xun Huang et al. CELL
- Epigenetic Restoration of Fetal-like IGF1 Signaling Inhibits Leukemia Stem Cell Activity
- (2018) Vincenzo Giambra et al. Cell Stem Cell
- Ezh2 loss propagates hypermethylation at T cell differentiation–regulating genes to promote leukemic transformation
- (2018) Changshan Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- LncRNA ANRIL regulates AML development through modulating the glucose metabolism pathway of AdipoR1/AMPK/SIRT1
- (2018) Lin-Yu Sun et al. Molecular Cancer
- Emerging EZH2 Inhibitors and Their Application in Lymphoma
- (2018) Jennifer K. Lue et al. Current Hematologic Malignancy Reports
- The silencing of long non-coding RNA ANRIL suppresses invasion, and promotes apoptosis of retinoblastoma cells through the ATM-E2F1 signaling pathway
- (2018) Yang Yang et al. BIOSCIENCE REPORTS
- PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia
- (2018) Ingrid M. Ariës et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Ezh2 programs TFH differentiation by integrating phosphorylation-dependent activation of Bcl6 and polycomb-dependent repression of p19Arf
- (2018) Fengyin Li et al. Nature Communications
- Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator
- (2018) Jung Kim et al. Cell Reports
- PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
- (2018) Laurie Herviou et al. Clinical Epigenetics
- Regulation of the Germinal Center Response
- (2018) Marisa Stebegg et al. Frontiers in Immunology
- Polycomb Repressive Complex 2-Mediated Chromatin Repression Guides Effector CD8 + T Cell Terminal Differentiation and Loss of Multipotency
- (2017) Simon M. Gray et al. IMMUNITY
- The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand
- (2017) Shan-zhong Yang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy
- (2017) Ying Huang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Heterogeneous epigenetic regulation of HACE1 in Burkitt- Lymphoma-derived cells
- (2017) Abdelilah Bouzelfen et al. LEUKEMIA RESEARCH
- EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma–Induced Epigenetic Suppression of Osteoblast Differentiation
- (2017) Juraj Adamik et al. MOLECULAR CANCER RESEARCH
- EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL
- (2017) Dorothy Brach et al. MOLECULAR CANCER THERAPEUTICS
- MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
- (2017) Peilong Li et al. MOLECULAR CANCER THERAPEUTICS
- Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner
- (2017) Konstantinos Dimopoulos et al. Molecular Oncology
- An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED
- (2017) Wei Qi et al. Nature Chemical Biology
- Epstein–Barr virus-associated lymphomas
- (2017) Claire Shannon-Lowe et al. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- HOX transcript antisense intergenic RNA represses E-cadherin expression by binding to EZH2 in gastric cancer
- (2017) Wen-Ming Chen et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity
- (2017) Shan He et al. Nature Communications
- EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop
- (2017) Wendy Béguelin et al. Nature Communications
- UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition
- (2017) Teresa Ezponda et al. Cell Reports
- Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED
- (2017) Ling Li et al. PLoS One
- Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation
- (2016) Xuejiao Song et al. BIOMEDICINE & PHARMACOTHERAPY
- Identification of novel EZH2 inhibitors through pharmacophore-based virtual screening and biological assays
- (2016) Yunlong Wu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma
- (2016) Junli Yan et al. BLOOD
- EZH2 coupled with HOTAIR to silence MicroRNA-34a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma
- (2016) Chi-Han Li et al. INTERNATIONAL JOURNAL OF CANCER
- The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD)
- (2016) Olga F. Sarmento et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia
- (2016) Vivien Schäfer et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas
- (2016) Rishi G. Vaswani et al. JOURNAL OF MEDICINAL CHEMISTRY
- LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2
- (2016) Xin Wang et al. Journal of Translational Medicine
- Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma
- (2016) A Bouska et al. LEUKEMIA
- Activation of the polycomb repressive complex pathway in the bone marrow resident cells of diffuse large B-cell lymphoma patients
- (2016) Eun Ji Oh et al. LEUKEMIA & LYMPHOMA
- An RB-EZH2 Complex Mediates Silencing of Repetitive DNA Sequences
- (2016) Charles A. Ishak et al. MOLECULAR CELL
- Elevated RNA expression of long non-coding HOTAIR promotes cell proliferation and predicts a poor prognosis in patients with diffuse large B cell lymphoma
- (2016) YULING YAN et al. Molecular Medicine Reports
- An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation
- (2016) George P Souroullas et al. NATURE MEDICINE
- DNA-PK-mediated phosphorylation of EZH2 regulates the DNA damage-induced apoptosis to maintain T-cell genomic integrity
- (2016) Y Wang et al. Cell Death & Disease
- Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia
- (2016) Etienne Danis et al. Cell Reports
- MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs
- (2016) C David Wood et al. eLife
- Growth Inhibition Accompanied by MOB1 Upregulation in Human Acute Lymphoid Leukemia Cells by 3-Deazaneplanocin A
- (2015) Jianzhen Shen et al. BIOCHEMICAL GENETICS
- Therapeutic targeting of HES1 transcriptional programs in T-ALL
- (2015) Stephanie A. Schnell et al. BLOOD
- The Chromatin-Modifying Enzyme Ezh2 Is Critical for the Maintenance of Regulatory T Cell Identity after Activation
- (2015) Michel DuPage et al. IMMUNITY
- Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma
- (2015) Jiro Kikuchi et al. JOURNAL OF CLINICAL INVESTIGATION
- EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches
- (2015) V. D’Angelo et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Coupling of T cell receptor specificity to natural killer T cell development by bivalent histone H3 methylation
- (2015) Marc-Werner Dobenecker et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors
- (2015) V Gibaja et al. ONCOGENE
- LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer
- (2015) Y-w Liu et al. Cell Death & Disease
- EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity
- (2015) John E. Campbell et al. ACS Medicinal Chemistry Letters
- Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas
- (2015) M A Lunning et al. Blood Cancer Journal
- Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors
- (2015) Theresa Baker et al. Oncotarget
- EZH2 is crucial for both differentiation of regulatory T cells and T effector cell expansion
- (2015) Xiang-Ping Yang et al. Scientific Reports
- Mutational spectrum of adult T-ALL
- (2015) Martin Neumann et al. Oncotarget
- LncRNA: A link between RNA and cancer
- (2014) Guodong Yang et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors
- (2014) Jimin Woo et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The polycomb repressive complex 2 governs life and death of peripheral T cells
- (2014) Y. Zhang et al. BLOOD
- c-Rel Regulates Ezh2 Expression in Activated Lymphocytes and Malignant Lymphoid Cells
- (2014) Wen Hao Neo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Astemizole Arrests the Proliferation of Cancer Cells by Disrupting the EZH2-EED Interaction of Polycomb Repressive Complex 2
- (2014) Xiangqian Kong et al. JOURNAL OF MEDICINAL CHEMISTRY
- FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma
- (2014) L Sehgal et al. LEUKEMIA
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- (2014) S. K. Knutson et al. MOLECULAR CANCER THERAPEUTICS
- A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation
- (2014) H. M. Ott et al. MOLECULAR CANCER THERAPEUTICS
- Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 in regulatory T cells
- (2014) Aaron Arvey et al. NATURE IMMUNOLOGY
- Oncogenic Y641 mutations in EZH2 prevent Jak2/β-TrCP-mediated degradation
- (2014) A A Sahasrabuddhe et al. ONCOGENE
- Discovery and Optimization of Tetramethylpiperidinyl Benzamides as Inhibitors of EZH2
- (2014) Christopher G. Nasveschuk et al. ACS Medicinal Chemistry Letters
- Regulation of p53 and Rb Links the Alternative NF-κB Pathway to EZH2 Expression and Cell Senescence
- (2014) Alessio Iannetti et al. PLoS Genetics
- Epstein-Barr Virus Down-Regulates Tumor Suppressor DOK1 Expression
- (2014) Maha Siouda et al. PLoS Pathogens
- An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1
- (2013) Kyle D. Konze et al. ACS Chemical Biology
- EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity
- (2013) J. Yan et al. BLOOD
- EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
- (2013) Wendy Béguelin et al. CANCER CELL
- Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth
- (2013) Shivani Garapaty-Rao et al. CHEMISTRY & BIOLOGY
- BRCA1 is a negative modulator of the PRC2 complex
- (2013) Lan Wang et al. EMBO JOURNAL
- The Polycomb Protein Ezh2 Regulates Differentiation and Plasticity of CD4+ T Helper Type 1 and Type 2 Cells
- (2013) Damon J. Tumes et al. IMMUNITY
- Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis
- (2013) Marieta Caganova et al. JOURNAL OF CLINICAL INVESTIGATION
- Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity
- (2013) X Zhao et al. LEUKEMIA
- Targeted disruption of the EZH2–EED complex inhibits EZH2-dependent cancer
- (2013) Woojin Kim et al. Nature Chemical Biology
- Epstein - Barr Virus Transforming Protein LMP-1 Alters B Cells Gene Expression by Promoting Accumulation of the Oncoprotein ΔNp73α
- (2013) Rosita Accardi et al. PLoS Pathogens
- Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas
- (2012) Xinwei Zhang et al. CANCER CELL
- Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells
- (2012) W. Fiskus et al. CLINICAL CANCER RESEARCH
- Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia
- (2012) Jianhe Chen et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- A687V EZH2 is a gain-of-function mutation found in lymphoma patients
- (2012) Christina R. Majer et al. FEBS LETTERS
- Polycomb Antagonizes p300/CREB-binding Protein-associated Factor to SilenceFOXP3in a Kruppel-like Factor-dependent Manner
- (2012) Yuning Xiong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Epigenetic Histone Modification of Epstein-Barr Virus BZLF1 Promoter during Latency and Reactivation in Raji Cells
- (2012) T. Murata et al. JOURNAL OF VIROLOGY
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
- (2012) Jinghui Zhang et al. NATURE
- A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
- (2012) Sarah K Knutson et al. Nature Chemical Biology
- Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing
- (2012) NATURE GENETICS
- Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia
- (2012) Panagiotis Ntziachristos et al. NATURE MEDICINE
- HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer
- (2012) K Kim et al. ONCOGENE
- Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
- (2012) M. T. McCabe et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
- (2012) W. Qi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
- (2012) K. Xu et al. SCIENCE
- Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2
- (2012) Sharad K. Verma et al. ACS Medicinal Chemistry Letters
- Inhibition of Histone Lysine Methylation Enhances Cancer-Testis Antigen Expression in Lung Cancer Cells: Implications for Adoptive Immunotherapy of Cancer
- (2011) M. Rao et al. CANCER RESEARCH
- The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states
- (2011) Tim J. Wigle et al. FEBS LETTERS
- Cyclin-dependent Kinase 1 (CDK1)-mediated Phosphorylation of Enhancer of Zeste 2 (Ezh2) Regulates Its Stability
- (2011) Susan C. Wu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer
- (2011) Francesco Crea et al. Molecular Cancer
- Context-Specific Regulation of NF-κB Target Gene Expression by EZH2 in Breast Cancers
- (2011) Shuet Theng Lee et al. MOLECULAR CELL
- Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
- (2011) Ryan D. Morin et al. NATURE
- The Polycomb complex PRC2 and its mark in life
- (2011) Raphaël Margueron et al. NATURE
- EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis
- (2010) I. Velichutina et al. BLOOD
- Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation
- (2010) D. B. Yap et al. BLOOD
- Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA
- (2010) S. Kaneko et al. GENES & DEVELOPMENT
- CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells
- (2010) Yongkun Wei et al. NATURE CELL BIOLOGY
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
- (2010) Ryan D Morin et al. NATURE GENETICS
- Polycomb Target Genes Are Silenced in Multiple Myeloma
- (2010) Antonia Kalushkova et al. PLoS One
- Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas
- (2010) C. J. Sneeringer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Long Noncoding RNA as Modular Scaffold of Histone Modification Complexes
- (2010) M.-C. Tsai et al. SCIENCE
- NF-κB signaling modulation by EBV and KSHV
- (2010) Deilson Elgui de Oliveira et al. TRENDS IN MICROBIOLOGY
- Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells
- (2009) W. Fiskus et al. BLOOD
- DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
- (2009) T. B. Miranda et al. MOLECULAR CANCER THERAPEUTICS
- MYC stimulates EZH2 expression by repression of its negative regulator miR-26a
- (2008) S. Sander et al. BLOOD
- Roles of the EZH2 histone methyltransferase in cancer epigenetics
- (2008) Jeffrey A. Simon et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More